Skip to main content
Evidence Snapshot

5-hydroxytryptamine receptor 1D

CHEMBL1983 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:29:58Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1983
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats 5-hydroxytryptamine receptor 1D as ChEMBL target CHEMBL1983, mapped to UniProt P28221. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
5-hydroxytryptamine receptor 1D
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1983
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P28221
5-hydroxytryptamine receptor 1D
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why 5-hydroxytryptamine receptor 1D matters

As of 2026-09-13

5-hydroxytryptamine receptor 1D is reviewed as 5-hydroxytryptamine receptor 1D (UniProt P28221); 5-hydroxytryptamine receptor 1D shows approved-linked disease relevance led by migraine disorder. 5 more disease programs remain visible in the same review block.; 10 linked drugs keep this evidence frame grounded.; the current evidence base includes 31 approved drugs, 2107 compounds, and 434 assays, with lead potency reaching pChEMBL 10.7.

Disease context
migraine disorder

5-hydroxytryptamine receptor 1D shows approved-linked disease relevance led by migraine disorder. 5 more disease programs remain visible in the same review block. 10 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ALMOTRIPTAN MALATE, DIHYDROERGOTAMINE MESYLATE, ELETRIPTAN HYDROBROMIDE.

Start review with migraine disorder because it currently carries approved-linked support. Linked drugs include ALMOTRIPTAN MALATE, DIHYDROERGOTAMINE MESYLATE, ELETRIPTAN HYDROBROMIDE, ERGOTAMINE TARTRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 10 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 31 approved drugs, 2107 compounds, and 434 assays for this target. The dominant activity type is KI. CHEMBL1242345 is the current potency anchor at pChEMBL 10.7.

Use CHEMBL1242345 as the tractability anchor when discussing potency (pChEMBL 10.7).

Activity source · ChEMBL 36 via Core Engine
31 approved pChEMBL 10.7
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why 5-hydroxytryptamine receptor 1D matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P28221, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why migraine disorder is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2107
Total Compounds
434
Total Assays
31
Approved Drugs
IC50: 435.0, KI: 1400.0, EC50: 196.0, KD: 3.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL1242345
 10.7 Ki —
No preferred name
CHEMBL1242081
 10.4 Ki —
No preferred name
CHEMBL513715
 10.3 Ki —
No preferred name
CHEMBL22744
 10.3 IC50 —
No preferred name
CHEMBL469374
 10.1 Ki —

Approved Drugs

Structure Compound First Approval
LASMIDITAN
CHEMBL3039520
 2020
BREXPIPRAZOLE
CHEMBL2105760
 2015
CARIPRAZINE HYDROCHLORIDE
CHEMBL2024517
 2015
VILAZODONE HYDROCHLORIDE
CHEMBL1615374
 2011
SILODOSIN
CHEMBL24778
 2008
PALIPERIDONE
CHEMBL1621
 2006
ARIPIPRAZOLE
CHEMBL1112
 2002
TEGASEROD MALEATE
CHEMBL1516474
 2002
FROVATRIPTAN
CHEMBL1279
 2001
NARATRIPTAN
CHEMBL1278
 1998
RIZATRIPTAN
CHEMBL905
 1998
ZOLMITRIPTAN
CHEMBL1185
 1997
AZELASTINE HYDROCHLORIDE
CHEMBL1200809
 1996
NEFAZODONE HYDROCHLORIDE
CHEMBL1200492
 1994
RISPERIDONE
CHEMBL85
 1993
SUMATRIPTAN
CHEMBL128
 1992
OXYMETAZOLINE
CHEMBL762
 1986
PRAZOSIN
CHEMBL2
 1976
ERGOTAMINE
CHEMBL442
 1948
MIANSERIN
CHEMBL6437
 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:29:58Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1983